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Figure 1. Acute and chronic GVHD
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allogeneic transplantation targeting Tcell depletion, with the
goal of decreasing the incidence and severity of both acute
and chronic GVHD. This is an update to the previously pub-
lished data where we showed that lower ATG dose resulted
in improved non-relapse mortality and infection rate
without compromising control of GVHD.
Methods: We retrospectively analyzed 136 consecutive
patients who received RIC HSCT between 2006 and 2010.
Following October 2007, ATG dosing was lowered from 7.5
mg/kg (R-ATG) to 6 mg/kg (r-ATG). Progression-free (PFS)
and overall survival (OS) were analyzed using the log-rank
test. Cumulative incidences of GVHD were analyzed using
Gray's test, accounting for competing risks.
Results: Thirty-nine patients received R-ATG and 97 received
r-ATG. There were no signiﬁcant differences in age, gender,
KPS, degree of HLA match, prior autografts, donor/recipient
CMV status, and CD34 cell dose between the two groups (P>
.15). More patients were transplanted with r-ATG than R-ATG
for CLL and fewer with AML/MDS/NHL/HD/other histologies
(P ¼ .02). Time to platelet engraftment as well as donor-cell
chimerism at days +30, +90, +180 were not signiﬁcantly
different between the groups, but time to neutrophil
engraftment was shorter with R-ATG (P ¼ .001). Proportions
of aGVHD II-IV were 52% and 41% (P ¼ .34) in r-ATG and
R-ATG respectively and proportions of cGVHD were 40% and
53% (P ¼ .23). Further, no signiﬁcant differences in the
cumulative incidence of GVHDwere observed (Figure 1). The
R-ATG group experienced more episodes of bacterial
infections than the r-ATG cohort (54% vs. 8%; P < .0001).
No differences in PFS (P ¼ .69) or OS (P ¼ .95) were
observed between the cohorts.
Conclusion: r-ATG did not result in an increase incidence of
acute or chronic GVHD. No PFS or OS differences were
observed between the cohorts; however, R-ATG resulted in
a higher proportion of bacterial infections.392
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Background: Chronic graft vs. host disease (cGVHD) is
a major cause of morbidity and mortality after allogeneic
HSCT. As an insidious onset and heterogeneous presentation
renders this disease difﬁcult to diagnose, there is a need for
validated diagnostic biomarkers. Previously, soluble amino-
peptidase N (CD13) was identiﬁed in a pediatric study as
a biomarker for early onset cGVHD (diagnosed 3-9 months
post transplant). Aminopeptidase N is a protease involved in
immunoregulation on several levels; functions include
attraction of T cells, antigen presentation, facilitation of
adhesion and phagocytosis. Although it is integrated in the
membrane of several cell types it can also be cleaved into
soluble aminopeptidase N. In this study, we tested the
potential plasma biomarker soluble aminopeptidase N in an
adult population of late onset cGVHD patients using botha targeted method (enzymatic assay) as well as a non-tar-
geted approach (proteomics).
Methods: Samples used in this study were frozen, EDTA-
treated plasma samples derived from a single institution
participating in the Chronic GVHD Consortium and consisted
of 17 cases and 21 time-matched controls, all from adult
patients. Cases were within 1 month of diagnosis of late-
onset cGVHD (onset >9 months post transplant). Time
posttransplant for cases vs. controls was 12 (9.2-26.8) vs. 11.9
(5.3-13.5) months, respectively. Other potential clinical
variables included age at sample collection, gender, graft
source, donor type, conditioning intensity, prior acute grade
II-IV GVHD, and months from sample collection. Amino-
peptidase N activity was determined by cleavage of
L-leucine-p-nitroaniline; quantitative proteomic analyses
were done with iTRAQ.
Results and Conclusions: Plasma from cGVHD patients had
signiﬁcantly higher mean levels of aminopeptidase N
enzyme activity than did plasma from control patients (0.30
vs. 0.18 mU/ml, respectively P ¼ .0008). Proteomic analyses
using the same samples revealed that this difference was not
restricted to activity; aminopeptidase N showed the most
signiﬁcant difference in protein levels corresponding to
presence or absence of cGVHD of all the proteins identiﬁed.
Relative amounts of soluble aminopeptidase N were 1.44 vs.
0.9, in cases and controls, respectively (P¼ .0042). This study
supports soluble aminopeptidase N as a potential diagnostic
biomarker in adult GVHD. These results will be validated in
a larger population which also includes early onset cGVHD.393
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Nonmyeloablative (NM) conditioning in allogeneic
transplantation is increasingly used in patients aged over 50
years with acute myeloid leukemia (AML). In this single-
center retrospective study, we report the results of NM and
myeloablative (MA) conditioning in 207 consecutive AML
